Expert Insights On CGT Formulation

1. Why Improving Drug Delivery Remains A Major Opportunity In Oncology 6/12/2026

   Engineered oncolytic viruses are emerging as a promising way to target tumors, deliver immune-stimulating payloads, and improve treatment of metastatic cancer.

2. Strategic Synthesis Of ASGCT And ASCO 2026 6/10/2026

   The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.

3. Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease 5/19/2026

   Autologous intradiscal therapy integrates delivery and biology into one system, highlighting the potential of cell therapies in complex, localized disease environments.

4. Transendocardial Cell Delivery In Post‑Acute Myocardial Infarction 5/4/2026

   Optimized delivery technologies will be central to next-generation therapies, serving as key differentiators for both clinical efficacy and operational feasibility.

5. Delivery Strategy For Next-Gen Cardiac Gene Therapies 3/12/2026

   As the field matures, the most transformative gene therapies in heart health are treating delivery not as an afterthought but as a fundamental principle.

6. Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors 3/5/2026

   Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

7. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

   In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

8. The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/15/2026

   The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).

9. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

   By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

10. Powering Cell Therapies With RNA: A New Code For Engineered Immunity 12/19/2025

    RNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.